US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.22

-0.0114-0.27%

Volume:139.72K

Turnover:589.27K

Market Cap:132.00M

PE:-1.02

High:4.28

Open:4.23

Low:4.17

Close:4.23

52wk High:50.40

52wk Low:4.17

Shares:31.29M

Float Shares:18.39M

Volume Ratio:0.71

T/O Rate:0.76%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.1300

EPS(LYR):-2.8503

ROE:-59.21%

ROA:-37.36%

PB:0.60

PE(LYR):-1.48

Loading ...

Overview Company News Filings

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment

MT Newswires Live

Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences

GeneDx, Beren Therapeutics launch NPC GenomeComplete

Cardiol Therapeutics to Showcase Cardiac Drug Pipeline at H.C. Wainwright Conference

ProQR Therapeutics doses first participant in AX-0811 clinical trial

William Blair Initiates Coverage on Obsidian Therapeutics With Outperform Rating

MT Newswires Live

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15

MT Newswires Live

Schrodinger Establishes Tectora Therapeutics With RA Capital, New Enterprise Associates

MT Newswires Live

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel

Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

Summit Therapeutics upgraded to Buy at Jefferies ahead of PFS data

D. Western Therapeutics Sees FY Loss Y800.00m

Neurizon Therapeutics Secures NIH Grant to Support Investigational ALS Treatment; Shares Up 31%

MT Newswires Live

Cyclerion Therapeutics trading halted, news pending

Press Release: Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting

Structure Therapeutics: Buy Rating Reaffirmed on Promising Obesity Pipeline and Extended Data, Price Target Maintained at $104

Keros Therapeutics Announces Share Repurchase Authorization Program

Sangamo Therapeutics Completes Key Technology Asset Sale

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/LENZ/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":4.2186,"timestamp":1789571353412,"preClose":4.23,"halted":0,"volume":139717,"delay":0,"changeRate":-0.002695035460992926,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"Trading","change":-0.0114,"latestTime":"09-16 11:09:15 EDT","open":4.23,"high":4.2771,"low":4.172,"amount":589270.8383510001,"amplitude":0.024846,"askPrice":4.22,"askSize":622,"bidPrice":4.21,"bidSize":506,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":4.23,"preHourTrading":{"tag":"盘前","latestPrice":4.2048,"preClose":4.23,"latestTime":"09:25 EDT","volume":813,"amount":3427.8884849999995,"timestamp":1789565102395,"change":-0.0252,"changeRate":-0.005957,"amplitude":0.034326},"postHourTrading":{"tag":"盘后","latestPrice":4.2983,"preClose":4.23,"latestTime":"19:30 EDT","volume":15901,"amount":67483.3442,"timestamp":1789515006325,"change":0.0683,"changeRate":0.016147,"amplitude":0.016147},"volumeRatio":0.713741,"impliedVol":0.7985,"impliedVolPercentile":0.1235},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":18393300,"roa":"-37.36%","roe":"-59.21%","lyrEps":-2.850329,"volumeRatio":0.713741,"shares":31289969,"dividePrice":0,"high":4.2771,"amplitude":0.024846,"preClose":4.23,"low":4.172,"week52Low":4.172,"pbRate":"0.60","psRate":"6.15","week52High":50.4,"institutionHeld":0,"latestPrice":4.2186,"committee":-0.102837,"eps":-4.13,"divideRate":0,"volume":139717,"delay":0,"ttmEps":-4.13,"open":4.23,"prevYearClose":16,"prevWeekClose":4.52,"prevMonthClose":5.21,"prevQuarterClose":5.68,"fiveDayClose":4.91,"twentyDayClose":4.77,"sixtyDayClose":5.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LENZ","fiscalQuarterEnding":"2026/06","expectedEps":-1.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-1.02},{"market":"US","date":"2026-05-11","symbol":"LENZ","fiscalQuarterEnding":"2026/03","expectedEps":-1.1,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-1.32},{"market":"US","date":"2026-03-24","symbol":"LENZ","fiscalQuarterEnding":"2025/12","expectedEps":-0.91,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.16},{"market":"US","date":"2026-01-07","symbol":"LENZ","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1767762000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-05","symbol":"LENZ","fiscalQuarterEnding":"2025/09","expectedEps":-0.67,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762318800000,"reportTimeType":"pre","actualEps":-0.59}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.2857,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2857,"analysts":7,"updateTime":1786593600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2026-09-15","current":-1.021453,"percent":1,"low":-26.69966,"twenty":-16.219821,"median":-9.723534,"eighty":-5.168633,"high":-1.114656,"avg":-10.473331,"sd":6.21597,"marketCap":140448933},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-13","current":-17.439532,"twenty":-14.747436,"median":-10.384797,"eighty":-7.264924,"marketCap":832563235},{"date":"2025-06-20","current":-17.704839,"twenty":-14.88454,"median":-10.454615,"eighty":-7.299361,"marketCap":845229004},{"date":"2025-06-27","current":-17.752005,"twenty":-15.005667,"median":-10.623361,"eighty":-7.425628,"marketCap":847480696},{"date":"2025-07-03","current":-19.178768,"twenty":-15.33581,"median":-10.694071,"eighty":-7.451903,"marketCap":915594389},{"date":"2025-07-11","current":-20.198727,"twenty":-15.529319,"median":-10.766979,"eighty":-7.459202,"marketCap":964287236},{"date":"2025-07-18","current":-20.381494,"twenty":-15.833323,"median":-10.791578,"eighty":-7.484747,"marketCap":973012543},{"date":"2025-07-25","current":-19.691695,"twenty":-16.100113,"median":-11.044571,"eighty":-7.492045,"marketCap":940081543},{"date":"2025-08-01","current":-16.20487,"twenty":-16.158905,"median":-11.077981,"eighty":-7.667213,"marketCap":849102797},{"date":"2025-08-08","current":-17.484059,"twenty":-16.20487,"median":-11.141188,"eighty":-7.667213,"marketCap":916129723},{"date":"2025-08-15","current":-22.268769,"twenty":-16.33076,"median":-11.193196,"eighty":-7.674511,"marketCap":1166838947},{"date":"2025-08-22","current":-21.691773,"twenty":-16.434778,"median":-11.220775,"eighty":-7.693556,"marketCap":1136605525},{"date":"2025-08-29","current":-20.793619,"twenty":-16.611183,"median":-11.233899,"eighty":-7.743848,"marketCap":1089544067},{"date":"2025-09-05","current":-21.729877,"twenty":-16.749673,"median":-11.252126,"eighty":-7.89274,"marketCap":1138602072},{"date":"2025-09-12","current":-22.214335,"twenty":-16.928962,"median":-11.290275,"eighty":-7.953319,"marketCap":1163986737},{"date":"2025-09-19","current":-22.693351,"twenty":-17.073997,"median":-11.339198,"eighty":-7.982513,"marketCap":1189086182},{"date":"2025-09-26","current":-21.789753,"twenty":-17.210778,"median":-11.419321,"eighty":-7.998378,"marketCap":1141739502},{"date":"2025-10-03","current":-26.302295,"twenty":-17.347559,"median":-11.473592,"eighty":-8.003646,"marketCap":1378187678},{"date":"2025-10-10","current":-25.175521,"twenty":-17.497557,"median":-11.534645,"eighty":-8.0071,"marketCap":1319146940},{"date":"2025-10-17","current":-22.018374,"twenty":-17.690689,"median":-11.749464,"eighty":-8.107241,"marketCap":1153718783},{"date":"2025-10-24","current":-16.034033,"twenty":-17.707197,"median":-11.991418,"eighty":-8.145558,"marketCap":840151237},{"date":"2025-10-31","current":-15.563946,"twenty":-17.690689,"median":-12.292165,"eighty":-8.168128,"marketCap":815519652},{"date":"2025-11-07","current":-10.439663,"twenty":-17.665927,"median":-12.292165,"eighty":-8.196087,"marketCap":614718687},{"date":"2025-11-14","current":-14.07658,"twenty":-17.595178,"median":-12.325665,"eighty":-8.25011,"marketCap":828871278},{"date":"2025-11-21","current":-14.730193,"twenty":-17.553908,"median":-12.761733,"eighty":-8.286974,"marketCap":867357940},{"date":"2025-11-28","current":-16.218091,"twenty":-17.524554,"median":-12.861347,"eighty":-8.308212,"marketCap":954969853},{"date":"2025-12-05","current":-14.825843,"twenty":-17.466248,"median":-13.119398,"eighty":-8.337771,"marketCap":872990135},{"date":"2025-12-12","current":-13.01911,"twenty":-17.42774,"median":-13.221067,"eighty":-8.354198,"marketCap":766604240},{"date":"2025-12-19","current":-9.070865,"twenty":-17.407695,"median":-13.037789,"eighty":-8.414622,"marketCap":534119770},{"date":"2025-12-26","current":-9.108063,"twenty":-17.390007,"median":-12.866196,"eighty":-8.500376,"marketCap":536310068},{"date":"2026-01-02","current":-8.502276,"twenty":-17.333409,"median":-12.777948,"eighty":-8.502276,"marketCap":500639504},{"date":"2026-01-09","current":-8.098418,"twenty":-17.315721,"median":-12.328345,"eighty":-8.502276,"marketCap":476859127},{"date":"2026-01-16","current":-9.639455,"twenty":-17.280347,"median":-12.249123,"eighty":-8.498134,"marketCap":567600037},{"date":"2026-01-23","current":-11.302713,"twenty":-17.228465,"median":-12.093174,"eighty":-8.501448,"marketCap":665537640},{"date":"2026-01-30","current":-9.448154,"twenty":-17.210778,"median":-11.871572,"eighty":-8.502276,"marketCap":556335648},{"date":"2026-02-06","current":-7.42355,"twenty":-17.195449,"median":-11.633633,"eighty":-8.39709,"marketCap":437120866},{"date":"2026-02-13","current":-6.892157,"twenty":-17.156729,"median":-11.509772,"eighty":-8.290687,"marketCap":405830897},{"date":"2026-02-20","current":-6.403276,"twenty":-17.117721,"median":-11.432889,"eighty":-8.236123,"marketCap":377044126},{"date":"2026-02-27","current":-7.184423,"twenty":-17.08343,"median":-11.396709,"eighty":-8.118629,"marketCap":423040380},{"date":"2026-03-06","current":-6.40859,"twenty":-17.073997,"median":-11.306259,"eighty":-7.995871,"marketCap":377357026},{"date":"2026-03-13","current":-6.281056,"twenty":-17.036729,"median":-11.290275,"eighty":-7.848663,"marketCap":369847433},{"date":"2026-03-20","current":-6.105697,"twenty":-16.999628,"median":-11.252126,"eighty":-7.671592,"marketCap":359521743},{"date":"2026-03-27","current":-3.413108,"twenty":-16.980184,"median":-11.233899,"eighty":-7.489126,"marketCap":280308282},{"date":"2026-04-02","current":-3.569637,"twenty":-16.958959,"median":-11.220775,"eighty":-7.447644,"marketCap":293163583},{"date":"2026-04-10","current":-3.54673,"twenty":-16.933679,"median":-11.193196,"eighty":-7.269441,"marketCap":291282320},{"date":"2026-04-17","current":-3.680353,"twenty":-16.916201,"median":-11.141188,"eighty":-7.181235,"marketCap":302256358},{"date":"2026-04-24","current":-3.493281,"twenty":-16.878888,"median":-11.077981,"eighty":-6.952736,"marketCap":286892705},{"date":"2026-05-01","current":-3.428379,"twenty":-16.817122,"median":-11.044571,"eighty":-6.825202,"marketCap":281562458},{"date":"2026-05-08","current":-3.710895,"twenty":-16.761494,"median":-10.861657,"eighty":-6.578636,"marketCap":304764709},{"date":"2026-05-15","current":-2.097082,"twenty":-16.730518,"median":-10.778852,"eighty":-6.457565,"marketCap":228573532},{"date":"2026-05-22","current":-2.163245,"twenty":-16.709792,"median":-10.723495,"eighty":-6.429023,"marketCap":235785042},{"date":"2026-05-29","current":-2.298448,"twenty":-16.694346,"median":-10.694071,"eighty":-6.404339,"marketCap":250521608},{"date":"2026-06-05","current":-2.071192,"twenty":-16.632408,"median":-10.560046,"eighty":-6.370576,"marketCap":225751636},{"date":"2026-06-12","current":-1.869826,"twenty":-16.608825,"median":-10.439663,"eighty":-6.329861,"marketCap":203803561},{"date":"2026-06-18","current":-1.8238,"twenty":-16.599392,"median":-10.388191,"eighty":-6.238545,"marketCap":198786857},{"date":"2026-06-26","current":-1.585037,"twenty":-16.591349,"median":-10.356288,"eighty":-6.201347,"marketCap":172762710},{"date":"2026-07-02","current":-1.665584,"twenty":-16.562409,"median":-10.323331,"eighty":-6.136275,"marketCap":181541941},{"date":"2026-07-10","current":-1.665584,"twenty":-16.458857,"median":-10.297741,"eighty":-6.098214,"marketCap":181541941},{"date":"2026-07-17","current":-1.403808,"twenty":-16.42504,"median":-10.207556,"eighty":-5.994366,"marketCap":153009442},{"date":"2026-07-24","current":-1.452711,"twenty":-16.399781,"median":-10.175633,"eighty":-5.904593,"marketCap":158339689},{"date":"2026-07-31","current":-1.656954,"twenty":-16.359791,"median":-10.130408,"eighty":-5.831073,"marketCap":180601309},{"date":"2026-08-07","current":-1.501614,"twenty":-16.336075,"median":-10.052902,"eighty":-5.780516,"marketCap":163669936},{"date":"2026-08-14","current":-1.147074,"twenty":-16.332656,"median":-9.910465,"eighty":-5.64279,"marketCap":144533577},{"date":"2026-08-21","current":-1.162036,"twenty":-16.31728,"median":-9.875604,"eighty":-5.484249,"marketCap":146418798},{"date":"2026-08-28","current":-1.19944,"twenty":-16.297238,"median":-9.783769,"eighty":-5.425546,"marketCap":151131849},{"date":"2026-09-04","current":-1.453791,"twenty":-16.251993,"median":-9.763078,"eighty":-5.336455,"marketCap":183180599},{"date":"2026-09-11","current":-1.176997,"twenty":-16.223282,"median":-9.734689,"eighty":-5.236314,"marketCap":148304018},{"date":"2026-09-15","current":-1.114656,"twenty":-16.219821,"median":-9.723534,"eighty":-5.168633,"marketCap":140448933}],"updateTime":1789571355795},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666290535","title":"ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2666290535","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666290535?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:23","pubTimestamp":1788960232,"startTime":"0","endTime":"0","summary":"ProQR Therapeutics  said Wednesday it has dosed the first participant in a phase 1 trial of AX-0811, a potential disease-modifying treatment for cholestatic liver diseases.The study will evaluate AX-0811's safety, tolerability, pharmacokinetics and pharmacodynamic biomarkers in healthy volunteers, ProQR Therapeutics said.Target engagement data from the first two cohorts are expected in early January 2027, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4539","PRQR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666363205","title":"Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2666363205","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666363205?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:00","pubTimestamp":1788958800,"startTime":"0","endTime":"0","summary":"Grand Cayman, Cayman Islands, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interf","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358748/0/en/silexion-therapeutics-to-participate-in-september-2026-industry-and-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","SLXN","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533951","title":"GeneDx, Beren Therapeutics launch NPC GenomeComplete","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533951","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533951?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:36","pubTimestamp":1788957412,"startTime":"0","endTime":"0","summary":"GeneDx (WGS) announced a collaboration with Beren Therapeutics to launch the NPC GenomeComplete Sponsored Testing Program. The program provides no-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genedx-beren-therapeutics-launch-npc-genomecomplete-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genedx-beren-therapeutics-launch-npc-genomecomplete-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","WGS","LENZ","BK4196","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666051538","title":"Cardiol Therapeutics to Showcase Cardiac Drug Pipeline at H.C. Wainwright Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666051538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666051538?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:18","pubTimestamp":1788956307,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Cardiol Therapeutics ( ($TSE:CRDL) ). Cardiol Therapeutics said it will take part in a fireside chat at the H.C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-to-showcase-cardiac-drug-pipeline-at-h-c-wainwright-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cardiol-therapeutics-to-showcase-cardiac-drug-pipeline-at-h-c-wainwright-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538091","title":"ProQR Therapeutics doses first participant in AX-0811 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538091?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:15","pubTimestamp":1788956125,"startTime":"0","endTime":"0","summary":"ProQR Therapeutics (PRQR) announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. Publi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","BK4007","BK4195","HYLG","IDNA","AX","GDOC","BK4139","BK4211","LU1861220207.SGD","LU2360107671.USD","PRQR","BK4539","LENZ","LU1861217088.USD","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538480","title":"William Blair Initiates Coverage on Obsidian Therapeutics With Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538480","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538480?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:11","pubTimestamp":1788955917,"startTime":"0","endTime":"0","summary":"William Blair Initiates Coverage on Obsidian Therapeutics With Outperform Rating","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666358001","title":"Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2666358001","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666358001?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:45","pubTimestamp":1788954300,"startTime":"0","endTime":"0","summary":"- Independent Safety Monitoring Committee recommends advancement to Cohort 2 following blinded review of Cohort 1 safety and tolerability data – - Pharmacokinetic observations at the lowest dose evalu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358540/0/en/serina-therapeutics-reports-cohort-1-observations-from-ser-252-registrational-study-in-advanced-parkinson-s-disease-and-advances-to-cohort-2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMC","LU0757428866.USD","AEIS","IE0031619046.USD","BK4539","IE00B19Z4B17.USD","BK4007","BK4157","LU2089985449.USD","LU1815336091.USD","LU0274383776.USD","LU2931357623.SGD","BK4144","IE00B7SZL793.SGD","IE00B66KJ199.SGD","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580195","title":"Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580195","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580195?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:42","pubTimestamp":1788954172,"startTime":"0","endTime":"0","summary":"Summit Therapeutics Inc (SMMT) has an average rating of overweight and mean price target of $29.06, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666958050","title":"Schrodinger Establishes Tectora Therapeutics With RA Capital, New Enterprise Associates","url":"https://stock-news.laohu8.com/highlight/detail?id=2666958050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666958050?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:33","pubTimestamp":1788953580,"startTime":"0","endTime":"0","summary":"Schrodinger (SDGR), along with New Enterprise Associates and RA Capital Management, established a new biotechnology company named Tectora Therapeutics, according to a Wednesday statement.Concurrently,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4585","BK4588","SDGR","EFSC","BK4211","BK4007","BK4539","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666800915","title":"Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2666800915","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666800915?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:30","pubTimestamp":1788953400,"startTime":"0","endTime":"0","summary":"CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358524/0/en/context-therapeutics-announces-first-patient-dosed-in-phase-1-trial-of-ct-202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","LENZ","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666796587","title":"Autolus Therapeutics granted RMAT designation for obecabtagene autoleucel","url":"https://stock-news.laohu8.com/highlight/detail?id=2666796587","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666796587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:15","pubTimestamp":1788952531,"startTime":"0","endTime":"0","summary":"Autolus Therapeutics (AUTL) announced that the FDA has granted regenerative medicine advanced therapy, or RMAT, designation to obecabtagene autoleu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-granted-rmat-designation-for-obecabtagene-autoleucel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/autolus-therapeutics-granted-rmat-designation-for-obecabtagene-autoleucel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4585","BK4539","AUTL","LABU","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666941587","title":"Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2666941587","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666941587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"Enrollment in LUMINA, the pivotal Phase 2 study of obe-cel in refractory lupus nephritis, is ongoingLONDON and GAITHERSBURG, Md., Sept.  09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358486/0/en/autolus-therapeutics-announces-fda-rmat-designation-granted-to-obe-cel-for-the-treatment-of-systemic-lupus-erythematosus-and-lupus-nephritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK4077","BK4007","ACR","BK4139","LENZ","BK4585","BK4110","SLE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587394","title":"Summit Therapeutics upgraded to Buy at Jefferies ahead of PFS data","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587394?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:50","pubTimestamp":1788951029,"startTime":"0","endTime":"0","summary":"As previously reported, Jefferies upgraded Summit Therapeutics (SMMT) to Buy from Hold with a price target of $25, up from $15, ahead of HARMONi-3 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-upgraded-to-buy-at-jefferies-ahead-of-pfs-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-upgraded-to-buy-at-jefferies-ahead-of-pfs-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666586904","title":"D. Western Therapeutics Sees FY Loss Y800.00m","url":"https://stock-news.laohu8.com/highlight/detail?id=2666586904","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666586904?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:47","pubTimestamp":1788943620,"startTime":"0","endTime":"0","summary":"D. Western Therapeutics Institute Inc. also released the following forecasts:. Results are based on Japanese accounting standards.This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","BK4168","BK4539","WRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666301515","title":"Neurizon Therapeutics Secures NIH Grant to Support Investigational ALS Treatment; Shares Up 31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666301515","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666301515?lang=en_us&edition=fundamental","pubTime":"2026-09-09 11:09","pubTimestamp":1788923345,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said the US National Institutes of Health  has awarded a multimillion-dollar, multi-year grant to support an expanded access protocol  for its investigational amyotrophic lateral sclerosis  therapy NUZ-001, according to a Wednesday filing with the Australian bourse.The program is expected to provide up to 200 ALS patients who are ineligible for clinical trials with access to NUZ-001 for up to 96 weeks, alongside the ongoing phase two and three Healey ALS platform trial, per the filing.The company will serve as the regulatory sponsor and provide the drug, while the Healey and AMG Center for ALS will oversee clinical operations, the filing said.The EAP is fully funded by the NIH and is expected to involve about 20 clinical sites across the US, alongside a national virtual site, with enrolment targeted to begin in the first quarter of 2027, subject to regulatory and operational approvals, the filing added.The company's shares jumped 31% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","BK7096","LENZ","NUZ.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666035943","title":"Cyclerion Therapeutics trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2666035943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666035943?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:50","pubTimestamp":1788911412,"startTime":"0","endTime":"0","summary":"19:50 EDT Cyclerion Therapeutics (CYCN) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cyclerion-therapeutics-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cyclerion-therapeutics-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CYCN","BK4539","LENZ","KRSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370726","title":"Press Release: Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370726?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:59","pubTimestamp":1788904740,"startTime":"0","endTime":"0","summary":"TAMPA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) (\"Inhibitor\" or the \"Company\") today highlighted several important developments disclosed in its Quarterly Re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4232","BK4539","INTI","BK4022","BK4585","LABU","R","BK4588","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666908370","title":"Structure Therapeutics: Buy Rating Reaffirmed on Promising Obesity Pipeline and Extended Data, Price Target Maintained at $104","url":"https://stock-news.laohu8.com/highlight/detail?id=2666908370","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666908370?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:15","pubTimestamp":1788902122,"startTime":"0","endTime":"0","summary":"Structure Therapeutics, Inc. Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Dolezal fr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/structure-therapeutics-buy-rating-reaffirmed-on-promising-obesity-pipeline-and-extended-data-price-target-maintained-at-104-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/structure-therapeutics-buy-rating-reaffirmed-on-promising-obesity-pipeline-and-extended-data-price-target-maintained-at-104-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666713377","title":"Keros Therapeutics Announces Share Repurchase Authorization Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666713377","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666713377?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:38","pubTimestamp":1788899909,"startTime":"0","endTime":"0","summary":"Keros Therapeutics ( ($KROS) ) just unveiled an announcement. On September 8, 2026, Keros Therapeutics announced that its board had authorized a $5...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/keros-therapeutics-announces-share-repurchase-authorization-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/keros-therapeutics-announces-share-repurchase-authorization-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","KROS","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377200","title":"Sangamo Therapeutics Completes Key Technology Asset Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377200?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:32","pubTimestamp":1788899575,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics ( ($SGMOQ) ) has issued an announcement. On September 4, 2026, Sangamo Therapeutics completed the court-approved sale of subst...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sangamo-therapeutics-completes-key-technology-asset-sale?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sangamo-therapeutics-completes-key-technology-asset-sale?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}